{
     "PMID": "8982649",
     "OWN": "NLM",
     "STAT": "MEDLINE",
     "DCOM": "19970321",
     "LR": "20161124",
     "IS": "0014-2999 (Print) 0014-2999 (Linking)",
     "VI": "316",
     "IP": "1",
     "DP": "1996 Nov 28",
     "TI": "Raphe 5-HT1A autoreceptors, but not postsynaptic 5-HT1A receptors or beta-adrenoceptors, restrain the citalopram-induced increase in extracellular 5-hydroxytryptamine in vivo.",
     "PG": "43-7",
     "AB": "In vivo microdialysis in rat ventral hippocampus was used (i) to verify the importance of 5-HT1A autoreceptors in the raphe as targets for drugs that enhance the citalopram-induced elevation of forebrain 5-hydroxytryptamine (5-HT), and (ii) to further examine the specificity of (-)-penbutolol in this regard. The selective 5-HT1A receptor antagonist WAY100635 (s.c., or intra-raphe) or the mixed 5-HT1A/1B/beta-adrenoceptor antagonist (-)-penbutolol (s.c.), potentiated the citalopram-induced 5-HT rise, whereas local \"reverse' dialysis of WAY100635 into the ventral hippocampus did not. Furthermore, the (-)-penbutolol-induced augmentation proved stereoselective and not mediated by beta-adrenoceptors (no effect of s.c. (+)-penbutolol, or beta 1- and beta 2-adrenoceptor blockers (betaxolol, ICI118.551)). These data provide direct evidence that increased stimulation of 5-HT1A autoreceptors in the midbrain raphe impedes the effect of citalopram on forebrain extracellular 5-HT, whereas neither postsynaptic 5-HT1A receptors nor beta-adrenoceptors appear to be involved.",
     "FAU": [
          "Hjorth, S",
          "Bengtsson, H J",
          "Milano, S"
     ],
     "AU": [
          "Hjorth S",
          "Bengtsson HJ",
          "Milano S"
     ],
     "AD": "Department of Pharmacology, University of Goteborg, Sweden. Stephan.Hjorth@pharm.gu.se",
     "LA": [
          "eng"
     ],
     "PT": [
          "Journal Article",
          "Research Support, Non-U.S. Gov't"
     ],
     "PL": "Netherlands",
     "TA": "Eur J Pharmacol",
     "JT": "European journal of pharmacology",
     "JID": "1254354",
     "RN": [
          "0 (Adrenergic beta-Antagonists)",
          "0 (Piperazines)",
          "0 (Propanolamines)",
          "0 (Pyridines)",
          "0 (Receptors, Adrenergic, beta)",
          "0 (Receptors, Serotonin)",
          "0 (Receptors, Serotonin, 5-HT1)",
          "0 (Serotonin Antagonists)",
          "0 (Serotonin Uptake Inhibitors)",
          "0DHU5B8D6V (Citalopram)",
          "333DO1RDJY (Serotonin)",
          "46OL1UC10R (ICI 118551)",
          "71IH826FEG",
          "(N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxa",
          "mide)",
          "78W62V43DY (Penbutolol)",
          "O0ZR1R6RZ2 (Betaxolol)"
     ],
     "SB": "IM",
     "MH": [
          "Adrenergic beta-Antagonists/pharmacology",
          "Animals",
          "Betaxolol/pharmacology",
          "Citalopram/*pharmacology",
          "Extracellular Space/metabolism",
          "Hippocampus/drug effects/metabolism/ultrastructure",
          "Male",
          "Microdialysis",
          "Penbutolol/pharmacology",
          "Piperazines/pharmacology",
          "Propanolamines/pharmacology",
          "Pyridines/pharmacology",
          "Raphe Nuclei/drug effects/*metabolism/*ultrastructure",
          "Rats",
          "Rats, Sprague-Dawley",
          "Receptors, Adrenergic, beta/*physiology",
          "Receptors, Serotonin/*physiology",
          "Receptors, Serotonin, 5-HT1",
          "Serotonin/*metabolism",
          "Serotonin Antagonists/pharmacology",
          "Serotonin Uptake Inhibitors/*pharmacology"
     ],
     "EDAT": "1996/11/28 00:00",
     "MHDA": "1996/11/28 00:01",
     "CRDT": [
          "1996/11/28 00:00"
     ],
     "PHST": [
          "1996/11/28 00:00 [pubmed]",
          "1996/11/28 00:01 [medline]",
          "1996/11/28 00:00 [entrez]"
     ],
     "AID": [
          "S0014299996007790 [pii]"
     ],
     "PST": "ppublish",
     "SO": "Eur J Pharmacol. 1996 Nov 28;316(1):43-7.",
     "term": "hippocampus"
}